. He can be reached at nsaraceno@mjhlifesciences.com.

Articles

IQVIA’s Doug Long offers a lay of the land, including trends and developing issues that are shaping the current market. 

Asembia 2025: A General Landscape of the Pharmaceutical Industry

Brett Casper explores the marketplace complexities that manufacturers face regularly. 

Asembia 2025: Navigating the Product Commercialization Process

Videos

Tiara Green, president, Accessia Health, highlights key themes from the upcoming discussion on how health equity, literacy, and social determinants are reshaping patient care—especially for those with chronic and rare conditions.

Asembia 2025: Bridging Health Gaps Through Equity and Education

A session dives into the trends surrounding specialty drugs and therapies, along with providing an overview of the drug development landscape. 

Asembia 2025: The Specialty Pharma Pipeline

Blake Powers, CEO, Medigi, discusses how face-to-face collaboration and streamlined commercialization strategies are helping life sciences companies deliver therapies more efficiently to patients.

Asembia 2025: The Role of Face-to-Face Connection in Pharma Commercialization

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Paul Levesque, CEO of Theratechnologies, describes the uneasiness behind regulatory complications. 

Why Distractions Are Detrimental to Business

Pharma Pulse 4/28/25: US Pharma Tariffs Would Raise US Drug Costs by $51 Billion Annually, Report Finds, How the Tariffs Expose Vulnerabilities in the Pharma Pipeline

The company’s branded form of nadofaragene firadenovec-vncg will also be produced at a hub in Parsippany, NJ. 

FDA Approves Additional Manufacturing Plant for Ferring’s Adstiladrin

Podcasts

Claire Riches highlights inefficiencies in the current drug approval process, while outlining the role of payers and insurers in shifting toward data-driven approval framework. 

Fast-Tracking the Future

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Paul Levesque, CEO of Theratechnologies, explains what the mindset be for companies who are just starting the reshoring process.

News